Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/129"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value |
"1.819"
|
| ?:content |
"Route of administration: oral
study duration: 5 days pre-treatment with atorvastatin then 3 days atorvastatin and clarithromycin
population: 36 from which 12 were randomly chosen to receive clarithromycin, 12 to receive azithromycin, and 12 to receive placebo the study
male: 16 or 17 female: 19 or 20 (data appears incorrect in paper)
ages: 24-33
AUC_i/AUC: 151.5/83.3ng/h/ml
This study investigated the potential for azithromycin and clarithromycin to inhibit the metabolism of atorvastatin. Although there was no interaction between azithromycin and atorvastatin, clarithromycin did have a significant effect on atorvastatin pharmacokinetic parameters. When coadministered, clarithromycin raised subject exposure (AUC24) by 82% and peak plasma concentrations by 56%. These data suggest that while azithromycin appears to be safe to coadminister with atorvastatin, clarithromycin should be avoided in patients taking this and similarly metabolized HMG-CoA inhibitors."
|
| dc:creator | |
| dc:date |
"06/05/2007 08:47:56"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ clarithromycin_increases_auc_atorvastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1972 }